WO2000071159A1 - Use of antibodies identifying the interleukin-2 receptor for preventing and/or treating hiv infections - Google Patents

Use of antibodies identifying the interleukin-2 receptor for preventing and/or treating hiv infections Download PDF

Info

Publication number
WO2000071159A1
WO2000071159A1 PCT/FR2000/001399 FR0001399W WO0071159A1 WO 2000071159 A1 WO2000071159 A1 WO 2000071159A1 FR 0001399 W FR0001399 W FR 0001399W WO 0071159 A1 WO0071159 A1 WO 0071159A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
receptor
interleukin
preventing
treating hiv
Prior art date
Application number
PCT/FR2000/001399
Other languages
French (fr)
Inventor
Pierre-François SERRES
Original Assignee
Hippocampe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hippocampe filed Critical Hippocampe
Priority to EP00931335A priority Critical patent/EP1178827A1/en
Priority to APAP/P/2001/002354A priority patent/AP2001002354A0/en
Priority to CA002373991A priority patent/CA2373991A1/en
Priority to AU49303/00A priority patent/AU4930300A/en
Priority to EA200101228A priority patent/EA200101228A1/en
Publication of WO2000071159A1 publication Critical patent/WO2000071159A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the invention relates to the use of antibodies recognizing the interleukin-2 receptor in the preparation of a medicament intended for the prevention and / or treatment of infections by an AIDS virus, in a mammal.
  • AIDS viruses include human immunodeficiency viruses (HIN), simian immunodeficiency viruses (SIN) and feline immunodeficiency viruses (FIN).
  • HIN human immunodeficiency viruses
  • SIN simian immunodeficiency viruses
  • FIN feline immunodeficiency viruses
  • the invention originates from the discovery of an analogy of three-dimensional structure between zones of interleukin-2 (IL-2) participating in the binding of IL-2 on the ⁇ , ⁇ , and ⁇ of the IL-2 receptor, and envelope proteins of AIDS viruses, in particular protein gp41 for HIN and SIN, gp36 for FIN, when these proteins are in the form of trimers. These trimers have already been described in the literature.
  • Another approach to vaccination against infections caused by AIDS viruses is a vaccine agent based on an immunogenic and not IL2-like envelope protein polypeptide (or a similar peptide mimicking said polypeptide).
  • an immunogenic and not IL2-like envelope protein polypeptide or a similar peptide mimicking said polypeptide.
  • This is the case in particular of the polypeptide 650-690, in particular 660-680 (in particular 667-672) of the protein gp41 of HIN1.
  • the numbering used here is that of the SWISSPROT bank (version 34), and reference is made in particular to the sequence having the code
  • E ⁇ N_HN1BR E ⁇ N_HN1BR.
  • any peptide homologous to the envelope protein of FIN or SIN in the case of a vaccine against these viruses.
  • the formulation of the vaccine compositions, and their mode of administration are known per se and will not be described further here.
  • RIL-2 interleukin-2 receptor
  • lymphocytes There are several types of cells, lymphocytes and others, which express on their surface one or more subunits of the IL-2 receptor.
  • antibodies or antibody fractions containing paratopes directed against the IL-2 receptor, to block, on the receptors of the target cells of the virus, the sites of interaction with the IL-2 and / or their vicinity, and thus prevent the attachment of viral particles to these cells and / or the penetration of said viral particles into said cells, in order to prevent or limit the infection of subjects having been exposed, or dreading d have been exposed to the virus.
  • infection here designates the penetration of the virus into the target cells.
  • the antibodies or antibody fraction used are those which recognize at least one of the ⁇ , ⁇ and ⁇ subunits of the IL-2 receptor, including the antibodies which recognize more precisely the binding site of the IL-2 on its receiver. In both cases, these antibodies can prevent the virus from attaching to the target cells, if only by steric hindrance.
  • analogs of the antibodies which have just been mentioned.
  • analog is understood here to mean any peptide mimicking the paratopes of these antibodies, or alternatively any peptide capable of binding to at least one of the ⁇ , ⁇ and ⁇ subunits of the IL-2 receptor.
  • Such peptides include fragments of IL-2 containing its binding site on the RIL-2 receptor, as well as any peptide capable of mimicking the binding site of IL-2 on its receptor.
  • This definition of analogs excludes IL-2 itself, given the known risks associated with the undesirable side effects of IL-2, especially at large doses.
  • the antibodies directed against the IL-2 receptor of the subject to be protected can be obtained according to the usual methods. Some have already been described. They may in particular be polyclonal antibodies purified by affinity chromatography, monoclonal antibodies, chimeric antibodies as described in patent FR-2,641,468, or bispecific antibodies recognizing two of the IL-2 receptor subunits.
  • the invention extends to the use of any antibody fragment containing a paratope directed against the IL-2 receptor, for example Fab, Fab 'and F (ab') 2 fragments.
  • an antibody is considered to have no marked immunosuppressive effect when, in conventional tests for lymphoproliferation in vitro (induced for example by the pokeweed mitogen, concanavalin A, or IL-2 ), the inhibition, caused by the antibody, of proliferation, does not exceed 25%, and in particular does not exceed 20%.
  • Such non-immunosuppressive antibodies can therefore be selected by simple routine experiments.
  • the amounts of antibody or antibody fractions required to block RIL-2 sites can be determined, for each species and for each antibody, by simple routine in vitro experiments. The same is true for the peptide analogues of these antibodies.
  • the medicament obtained according to the invention can be in the form of injectable solutions or in the form of lyophilized preparations making it possible to reconstitute an injectable solution at the time of use.
  • a medicament can be administered in vivo intravenously, or ex vivo by addition to blood samples intended to be reinjected.
  • blood samples intended to be reinjected for example, between 1 and 100 mg of active principle are administered per kg of body weight per day.
  • molar doses equivalent to those just indicated are used. Treatment is continued as long as the viral load of the treated individual is detectable.
  • Anti-RIL2 antibodies 33B31 also called ARIL-2 (anti- ⁇ RIL2); xlone A41
  • the cells are preincubated with at least one of the anti-RIL2 antibodies at a temperature of 4 ° C., one hour before being brought into contact with the virus.
  • the possible intracellular penetration of the virus is revealed with a fluorescent antibody (clone KC57 FITC) directed against the core of the virus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns the use of antibodies, or analogues blocking the interleukin-2 receptor which prevents the AIDS virus from fixing itself on its target cells and/or from penetrating into said cells. The invention is useful for treating HIV infections.

Description

Utilisation d'anticorps reconnaissant le récepteur de l'interleukine-2 dans la prévention et/ou le traitement des infections par les virus du SIDA. Use of antibodies recognizing the interleukin-2 receptor in the prevention and / or treatment of infections by AIDS viruses.
L'invention concerne l'utilisation d'anticorps reconnaissant le récepteur de l'interleukine-2 dans la préparation d'un médicament destiné à la prévention et/ou au traitement des infections par un virus du SIDA, chez un mammifère.The invention relates to the use of antibodies recognizing the interleukin-2 receptor in the preparation of a medicament intended for the prevention and / or treatment of infections by an AIDS virus, in a mammal.
Les virus du SIDA incluent les virus de l'immunodéficience humaine (HIN), les virus de l'immunodéficience simienne (SIN) et les virus de l'immunodéficience féline (FIN). L'invention tire son origine de la découverte d'une analogie de structure tridimensionnelle entre des zones de l'interleukine-2 (IL-2) participant à la fixation de l'IL-2 sur les sous-unités α, β, et γ du récepteur de l'IL-2, et des protéines d'enveloppe des virus du SIDA, notamment protéine gp41 pour HIN et SIN, gp36 pour FIN, lorsque ces protéines sont sous la forme de trimères. Ces trimères ont déjà été décrits dans la littérature.AIDS viruses include human immunodeficiency viruses (HIN), simian immunodeficiency viruses (SIN) and feline immunodeficiency viruses (FIN). The invention originates from the discovery of an analogy of three-dimensional structure between zones of interleukin-2 (IL-2) participating in the binding of IL-2 on the α, β, and γ of the IL-2 receptor, and envelope proteins of AIDS viruses, in particular protein gp41 for HIN and SIN, gp36 for FIN, when these proteins are in the form of trimers. These trimers have already been described in the literature.
Ces analogies de structure sont décrites plus particulièrement dans la demande de brevet FR-97 14387, déposée le 17 novembre 1997 par la demanderesse et dans la demande PCTJFR-9802447, déposée le 17 novembre 1998, qui lui correspond. Le contenu de ces demandes de brevet est incorporé par référence à la description de la présente demande. Dans les demandes de brevet qui viennent d'être mentionnées, on propose notamment de préparer un agent vaccinal contre le SIDA, à base d'un polypeptide comprenant un fragment d'une zone immunodominante IL2-like d'une protéine d'enveloppe du virus, ce polypeptide étant modifié de façon à induire une réponse immunitaire dirigée contre la protéine d'enveloppe mais non contre l'IL-2. Une autre approche de la vaccination contre les infections dues aux virus du SIDA, est un agent vaccinal à base d'un polypeptide de la protéine d'enveloppe (ou d'un peptide analogue mimant ledit polypeptide) immunogène et non IL2-like. C'est le cas notamment du polypeptide 650-690, notamment 660-680 (en particulier 667-672) de la protéine gp41 de HIN1. La numérotation utilisée ici est celle de la banque SWISSPROT (version 34), et on fait référence notamment à la séquence ayant pour codeThese structural analogies are described more particularly in patent application FR-97 14387, filed on November 17, 1997 by the applicant and in application PCTJFR-9802447, filed on November 17, 1998, which corresponds to it. The content of these patent applications is incorporated by reference into the description of the present application. In the patent applications which have just been mentioned, it is proposed in particular to prepare an AIDS vaccine agent, based on a polypeptide comprising a fragment of an IL2-like immunodominant zone of an envelope protein of the virus , this polypeptide being modified so as to induce an immune response directed against the envelope protein but not against IL-2. Another approach to vaccination against infections caused by AIDS viruses is a vaccine agent based on an immunogenic and not IL2-like envelope protein polypeptide (or a similar peptide mimicking said polypeptide). This is the case in particular of the polypeptide 650-690, in particular 660-680 (in particular 667-672) of the protein gp41 of HIN1. The numbering used here is that of the SWISSPROT bank (version 34), and reference is made in particular to the sequence having the code
EΝN_HN1BR. Bien entendu, on peut également utiliser tout peptide homologue de la protéine d'enveloppe de FIN ou SIN dans le cas d'un vaccin contre ces virus. La formulation des compositions vaccinales, et leur mode d'administration sont connus en soi et ne seront pas décrits davantage ici.EΝN_HN1BR. Of course, it is also possible to use any peptide homologous to the envelope protein of FIN or SIN in the case of a vaccine against these viruses. The formulation of the vaccine compositions, and their mode of administration are known per se and will not be described further here.
L'analogie de structure mentionnée ci-dessus a conduit les auteurs de la présente invention à penser que le récepteur de l'interleukine-2 (RIL-2) joue un rôle dans la fixation du virus sur ses cellules cibles et/ou sa pénétration dans lesdites cellules cibles.The structural analogy mentioned above has led the authors of the present invention to believe that the interleukin-2 receptor (RIL-2) plays a role in the attachment of the virus to its target cells and / or its penetration. in said target cells.
Il existe plusieurs types de cellules, lymphocytes et autres, qui expriment à leur surface une ou plusieurs sous-unités du récepteur de l'IL-2.There are several types of cells, lymphocytes and others, which express on their surface one or more subunits of the IL-2 receptor.
Il est donc possible d'utiliser des anticorps ou des fractions d'anticorps, contenant des paratopes dirigés contre le récepteur de l'IL-2, pour bloquer, sur les récepteurs des cellules cibles du virus, les sites d'interaction avec l'IL-2 et/ou leur voisinage, et empêcher ainsi la fixation des particules virales sur ces cellules et/ou la pénétration desdites particules virales dans lesdites cellules, afin de prévenir ou de limiter l'infection de sujets ayant été exposés, ou redoutant d'avoir été exposés, au virus. Le terme "infection" désigne ici la pénétration du virus dans les cellules cibles.It is therefore possible to use antibodies or antibody fractions, containing paratopes directed against the IL-2 receptor, to block, on the receptors of the target cells of the virus, the sites of interaction with the IL-2 and / or their vicinity, and thus prevent the attachment of viral particles to these cells and / or the penetration of said viral particles into said cells, in order to prevent or limit the infection of subjects having been exposed, or dreading d have been exposed to the virus. The term “infection” here designates the penetration of the virus into the target cells.
Les anticorps ou fraction d'anticorps utilisés sont ceux qui reconnaissent l'une au moins des sous-unités α, β et γ du récepteur de l'IL-2, y compris les anticorps qui reconnaissent plus précisément le site de fixation de l'IL-2 sur son récepteur. Dans les deux cas, ces anticorps peuvent empêcher la fixation du virus sur les cellules cibles, ne serait-ce que par empêchement stérique.The antibodies or antibody fraction used are those which recognize at least one of the α, β and γ subunits of the IL-2 receptor, including the antibodies which recognize more precisely the binding site of the IL-2 on its receiver. In both cases, these antibodies can prevent the virus from attaching to the target cells, if only by steric hindrance.
L'invention s'étend à l'utilisation d'analogues des anticorps qui viennent d'être mentionnés. On entend ici par "analogue" tout peptide mimant les paratopes de ces anticorps, ou encore tout peptide capable de se fixer sur l'une au moins des sous-unités α, β et γ du récepteur de l'IL-2. De tels peptides incluent des fragments de l'IL-2 contenant son site de fixation sur le récepteur RIL-2, ainsi que tout peptide capable de mimer le site de fixation de l'IL-2 sur son récepteur. Cette définition des analogues exclut toutefois l'IL-2 elle-même, compte tenu des risques connus liés aux effets secondaires indésirables de l'IL-2, notamment à doses importantes.The invention extends to the use of analogs of the antibodies which have just been mentioned. The term “analog” is understood here to mean any peptide mimicking the paratopes of these antibodies, or alternatively any peptide capable of binding to at least one of the α, β and γ subunits of the IL-2 receptor. Such peptides include fragments of IL-2 containing its binding site on the RIL-2 receptor, as well as any peptide capable of mimicking the binding site of IL-2 on its receptor. This definition of analogs, however, excludes IL-2 itself, given the known risks associated with the undesirable side effects of IL-2, especially at large doses.
Les anticorps dirigés contre le récepteur de l'IL-2 du sujet à protéger (IL-2 humaine ou IL-2 animale selon les cas) peuvent être obtenus selon les méthodes usuelles. Certains ont déjà été décrits. Il peut s'agir notamment d'anticorps polyclonaux purifiés par chromatographie d'affinité, d'anticorps monoclonaux, d'anticorps chimères tels que décrits dans le brevet FR-2 641 468, ou d'anticorps bispécifiques reconnaissant deux des sous-unités du récepteur de l'IL-2.The antibodies directed against the IL-2 receptor of the subject to be protected (human IL-2 or animal IL-2 as the case may be) can be obtained according to the usual methods. Some have already been described. They may in particular be polyclonal antibodies purified by affinity chromatography, monoclonal antibodies, chimeric antibodies as described in patent FR-2,641,468, or bispecific antibodies recognizing two of the IL-2 receptor subunits.
Bien entendu, l'invention s'étend à l'utilisation de tout fragment d'anticorps contenant un paratope dirigé contre le récepteur de l'IL-2, par exemple des fragments Fab, Fab' et F(ab')2.Of course, the invention extends to the use of any antibody fragment containing a paratope directed against the IL-2 receptor, for example Fab, Fab 'and F (ab') 2 fragments.
Le traitement avec des anticorps anti-RIL-2 n'affaiblit pas les défenses immunitaires, car il a été observé, lors des études ayant conduit à l'invention, que de tels anticorps n'ont généralement pas d'effet immunosuppresseur marqué.Treatment with anti-RIL-2 antibodies does not weaken the immune defenses, since it has been observed, during the studies leading to the invention, that such antibodies generally have no marked immunosuppressive effect.
Il ne peut pas être exclu cependant que certains anticorps anti-RIL-2 puissent avoir un effet immunosuppresseur. Un tel effet serait évidemment indésirable, et il est évident que seuls des anticorps n'ayant pas d'effet immunosuppresseur marqué peuvent être utilisés conformément à la présente invention.It cannot be excluded, however, that certain anti-RIL-2 antibodies may have an immunosuppressive effect. Such an effect would obviously be undesirable, and it is obvious that only antibodies having no marked immunosuppressive effect can be used in accordance with the present invention.
Dans la présente demande, on considère qu'un anticorps n'a pas d'effet immunosuppresseur marqué lorsque, dans des tests classiques de lymphoprolifération in vitro (induite par exemple par le mitogène du pokeweed, la concanavaline A, ou l'IL-2), l'inhibition, provoqué par l'anticorps, de la prolifération, n'excède pas 25 %, et en particulier n'excède pas 20 %. De tels anticorps non immunosuppresseurs peuvent donc être sélectionnés par de simples expériences de routine.In the present application, an antibody is considered to have no marked immunosuppressive effect when, in conventional tests for lymphoproliferation in vitro (induced for example by the pokeweed mitogen, concanavalin A, or IL-2 ), the inhibition, caused by the antibody, of proliferation, does not exceed 25%, and in particular does not exceed 20%. Such non-immunosuppressive antibodies can therefore be selected by simple routine experiments.
Les quantités d'anticorps ou de fractions d'anticorps nécessaires pour bloquer les sites RIL-2 peuvent être déterminées, pour chaque espèce et pour chaque anticorps, par de simples expériences de routine in vitro. Il en va de même pour les analogues peptidiques de ces anticorps.The amounts of antibody or antibody fractions required to block RIL-2 sites can be determined, for each species and for each antibody, by simple routine in vitro experiments. The same is true for the peptide analogues of these antibodies.
Le médicament obtenu selon l'invention, peut se présenter sous la forme de solutions injectables ou sous la forme de préparations lyophilisées permettant de reconstituer une solution injectable au moment de l'emploi. Un tel médicament peut être administré in vivo par voie intraveineuse, ou ex vivo par addition à des échantillons de sang destinés à être réinjectés. Dans le cas d'anticorps, on administre par exemple entre 1 et 100 mg de principe actif par kg de poids corporel et par jour. Pour des fragments d'anticorps ou d'autres analogues peptidiques, on utilise des doses molaires équivalentes à celles qui viennent d'être indiquées. Le traitement est poursuivi tant que la charge virale de l'individu traité est détectable.The medicament obtained according to the invention can be in the form of injectable solutions or in the form of lyophilized preparations making it possible to reconstitute an injectable solution at the time of use. Such a medicament can be administered in vivo intravenously, or ex vivo by addition to blood samples intended to be reinjected. In the case of antibodies, for example, between 1 and 100 mg of active principle are administered per kg of body weight per day. For fragments of antibodies or other peptide analogs, molar doses equivalent to those just indicated are used. Treatment is continued as long as the viral load of the treated individual is detectable.
Pour montrer que le blocage des sites RIL-2 par des anticorps est susceptible d'empêcher la pénétration du virus dans ses cellules cibles, on peut utiliser par exemple le modèle expérimental suivant :To show that blocking of RIL-2 sites by antibodies is susceptible to prevent penetration of the virus into its target cells, the following experimental model can be used, for example:
Cellules infectables exprimant les sous-unités α, β, et γ de l'IL-2 : MT4 ou HUT 102. Anticorps anti-RIL2 : 33B31 encore appelé ARIL-2 (anti-αRIL2) ; xlone A41Infectible cells expressing the α, β, and γ subunits of IL-2: MT4 or HUT 102. Anti-RIL2 antibodies: 33B31 also called ARIL-2 (anti-αRIL2); xlone A41
(anti-βRIL2) ; MAB284 commercialisé par R&D SYSTEM (anti-γRIL2).(anti-βRIL2); MAB284 marketed by R&D SYSTEM (anti-γRIL2).
Les cellules sont préincubées avec l'un au moins des anticorps anti-RIL2 à la température de 4°C, une heure avant la mise en contact avec le virus. On révèle la pénétration intracellulaire éventuelle du virus avec un anticorps fluorescent (clone KC57 FITC) dirigé contre le core du virus. The cells are preincubated with at least one of the anti-RIL2 antibodies at a temperature of 4 ° C., one hour before being brought into contact with the virus. The possible intracellular penetration of the virus is revealed with a fluorescent antibody (clone KC57 FITC) directed against the core of the virus.

Claims

REVENDICATIONS
1. Utilisation d'anticorps, ou de fragments ou d'analogues desdits anticorps, reconnaissant l'une au moins des sous-unités α, β et γ du récepteur de l'interleukine-2, dans la préparation d'un médicament destiné à la prévention et/ou au traitement des infections par les virus de l'immunodéficience, chez un mammifère.1. Use of antibodies, or fragments or analogs of said antibodies, recognizing at least one of the α, β and γ subunits of the interleukin-2 receptor, in the preparation of a medicament intended for preventing and / or treating infections with immunodeficiency viruses in a mammal.
2. Utilisation selon la revendication 1, dans laquelle ledit médicament est destiné à prévenir et/ou traiter des infections par un virus choisi parmi HIV, SIN et FIN. 2. Use according to claim 1, wherein said medicament is intended to prevent and / or treat infections by a virus chosen from HIV, INS and FIN.
PCT/FR2000/001399 1999-05-21 2000-05-22 Use of antibodies identifying the interleukin-2 receptor for preventing and/or treating hiv infections WO2000071159A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00931335A EP1178827A1 (en) 1999-05-21 2000-05-22 Use of antibodies identifying the interleukin-2 receptor for preventing and/or treating hiv infections
APAP/P/2001/002354A AP2001002354A0 (en) 1999-05-21 2000-05-22 Use of antibodies recognizing the interleukin-2 receptor in the prevention and /or treatment of infections by the AIDS viruses.
CA002373991A CA2373991A1 (en) 1999-05-21 2000-05-22 Use of antibodies identifying the interleukin-2 receptor for preventing and/or treating hiv infections
AU49303/00A AU4930300A (en) 1999-05-21 2000-05-22 Use of antibodies identifying the interleukin-2 receptor for preventing and/or treating hiv infections
EA200101228A EA200101228A1 (en) 1999-05-21 2000-05-22 USE OF ANTIBODIES THAT RECOGNIZE THE INTERLEUKIN-2 RECEPTOR FOR THE PREVENTION AND / OR TREATMENT OF INFECTIONS CAUSED BY AIDS VIRUSES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/06528 1999-05-21
FR9906528A FR2793691B1 (en) 1999-05-21 1999-05-21 USE OF ANTIBODIES RECOGNIZING THE INTERLEUKIN-2 RECEPTOR IN THE PREVENTION AND / OR TREATMENT OF AIDS VIRUS INFECTIONS

Publications (1)

Publication Number Publication Date
WO2000071159A1 true WO2000071159A1 (en) 2000-11-30

Family

ID=9545913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/001399 WO2000071159A1 (en) 1999-05-21 2000-05-22 Use of antibodies identifying the interleukin-2 receptor for preventing and/or treating hiv infections

Country Status (8)

Country Link
EP (1) EP1178827A1 (en)
AP (1) AP2001002354A0 (en)
AU (1) AU4930300A (en)
CA (1) CA2373991A1 (en)
EA (1) EA200101228A1 (en)
FR (1) FR2793691B1 (en)
OA (1) OA12311A (en)
WO (1) WO2000071159A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0340604A2 (en) * 1988-05-06 1989-11-08 Innothérapie S.A. Monoclonal antibody and its use
JPH024800A (en) * 1988-06-24 1990-01-09 Ube Ind Ltd Module for removing interleukin ii receptor and method for removing interleukin ii receptor using said module
EP0449769A1 (en) * 1990-03-16 1991-10-02 Sandoz Ltd. CD 25 binding molecules
WO1993011238A1 (en) * 1991-12-06 1993-06-10 Sumitomo Pharmaceuticals Company, Limited Humanized b-b10, an anti-il2 receptor antibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0340604A2 (en) * 1988-05-06 1989-11-08 Innothérapie S.A. Monoclonal antibody and its use
JPH024800A (en) * 1988-06-24 1990-01-09 Ube Ind Ltd Module for removing interleukin ii receptor and method for removing interleukin ii receptor using said module
EP0449769A1 (en) * 1990-03-16 1991-10-02 Sandoz Ltd. CD 25 binding molecules
WO1993011238A1 (en) * 1991-12-06 1993-06-10 Sumitomo Pharmaceuticals Company, Limited Humanized b-b10, an anti-il2 receptor antibody

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BELL K., ET AL.: "An immunotoxin directed against cd25 selectively kills hiv-infected pb", INTERNATIONAL CONFERENCE ON AIDS AND THE STD WORLD CONGRESS., XX, XX, vol. 02., 19 July 1992 (1992-07-19), XX, pages B160., XP002134285 *
DATABASE WPI Week 9008, Derwent World Patents Index; AN 1990-053531, XP002134286 *
J. BORVAK ET AL.: "Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection.", THE JOURNAL OF IMMUNOLOGY, vol. 155, no. 6, 15 September 1995 (1995-09-15), Baltimore, MD, USA, pages 3196 - 3204, XP002134283 *
K. BELL ET AL.: "Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 90, no. 4, 15 February 1993 (1993-02-15), Washington, DC, États-Unis, pages 1411 - 1415, XP002134282 *
M. KOTANI ET AL.: "Generation of monoclonal antibodies to the rabbit interleukin-2 receptor alpha chain (CD25) and its distribution in HTLV-1-transformed rabbit T cells.", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 84, no. 7, July 1993 (1993-07-01), Japon, pages 770 - 775, XP000891641 *
O. RAMILO ET AL.: "Role of CD25+ and CD25- T cells in acute HIV infection in vitro.", THE JOURNAL OF IMMUNOLOGY, vol. 11, no. 1, 1 June 1993 (1993-06-01), Baltimore, MD, USA, pages 5202 - 5208, XP002134284 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
US8182812B2 (en) 2002-11-15 2012-05-22 Genmab A/S Human monoclonal antibodies against CD25
US8961968B2 (en) 2002-11-15 2015-02-24 Genmab A/S Human monoclonal antibodies against CD25
US9598493B2 (en) 2002-11-15 2017-03-21 Genmab A/S Human monoclonal antibodies against CD25
US10703818B2 (en) 2002-11-15 2020-07-07 Genmab A/S Human monoclonal antibodies against CD25

Also Published As

Publication number Publication date
EP1178827A1 (en) 2002-02-13
FR2793691B1 (en) 2003-10-03
FR2793691A1 (en) 2000-11-24
EA200101228A1 (en) 2002-08-29
OA12311A (en) 2006-05-12
CA2373991A1 (en) 2000-11-30
AU4930300A (en) 2000-12-12
AP2001002354A0 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
Sopori et al. Effect of nicotine on the immune system: possible regulation of immune responses by central and peripheral mechanisms
FR2773156A1 (en) NOVEL ANTI-RETROVIRAL IMMUNOGENS (TOXOIDS), NOVEL PREPARATION METHODS AND APPLICATION TO AIDS PREVENTION AND TREATMENT
FR2766826A1 (en) VECTORS DERIVED FROM ANTIBODIES FOR TRANSFERRING SUBSTANCES IN CELLS
US7147849B2 (en) Pharmaceutical formulation
EP1169057B1 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
FR2622587A1 (en) LYSYL-ARGINYL-ASPARTYL-SERINE PEPTIDE AND ITS APPLICATIONS AS A MEDICAMENT, IN PARTICULAR ANTITHROMBOTICS
JP3215110B2 (en) Composition for treating chronic fatigue syndrome
EP1368372B1 (en) Peptides having affinity for the gp120 viral protein and use thereof
CA1273304A (en) Compositions and process for protecting lymphocytes t againtst the etiologic agent of lymphadenopathies and aquired immunodeficiency syndrome
WO2000071159A1 (en) Use of antibodies identifying the interleukin-2 receptor for preventing and/or treating hiv infections
FR2945952A1 (en) ANTI-CK8 ANTIBODIES FOR USE AS A MEDICINAL PRODUCT.
JP2003507011A (en) IL-16 antagonist
US5567805A (en) The cellular receptor for the CS3 peptide of human immunodeficiency virus
FR2828687A1 (en) NOVEL PEPTIDES AND THEIR USE AS MEDICAMENTS AGAINST IVF INFECTION IN CATS
JP5836968B2 (en) Method for treating IgE-mediated diseases
EP1041997B1 (en) Use of citrulline peptides derived from filaggrin for treating autoimmune diseases
EP0095426A1 (en) Synthetic polypeptides containing at least one sequence of the choleric B1 sub-unit toxin, and medicines containing them
FR2769226A1 (en) Use of neuronal potassium channel blockers, especially kaliotoxin peptides
EP1015018A1 (en) Veterinary medicine containing native or modified equine chorionic gonadotropin
LU88102A1 (en) POLYADENYLIC ACID COMPLEXES WITH POLYURIDYLIC ACID
FR2731355A1 (en) NOVEL IMMUNOGENS, NEW ANTIBODIES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
FR2668488A1 (en) New peptide(s) common to mycoplasm adhesion molecule and HIV proteins
Kabeya et al. Bovine leukaemia virus envelope peptides cause immunomodulation in BALB/c mice
EP0375767B1 (en) Peptides with protective properties with regard to a pathogenic virus of the hiv type in sensitive cells
CA3163277A1 (en) Immunogenic conjugate intended to induce an immune response directed against interleukin-6

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2373991

Country of ref document: CA

Ref document number: 2373991

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000931335

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200101228

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 09979271

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000931335

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000931335

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP